Royalty Pharma appoints Carole Ho and Elizabeth Weatherman to Board of Directors

Royalty Pharma plc

Carole Ho (CMO of Denali Therapeutics) and Elizabeth Weatherman (Special LP at Warburg Pincus) appointed effective July 17, 2025.
Independent board representation increases to >90% following external manager acquisition.
Both directors determined independent under Nasdaq standards; no family relationships with officers or directors.
They will receive compensation per Independent Director Compensation Policy detailed in April 2025 Proxy Statement.

item 5.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.